Study guide
8.2 Safety Reporting Timelines (Investigator-Sponsor-FDA-IRB)
SOCRA CCRP Certified Clinical Research Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Ethical Codes & Guidelines
1.1 The Nuremberg Code (1947) 1.2 The Declaration of Helsinki (1964) 1.3 The Belmont Report (1979)
2 Chapter 2: U.S. Federal Regulatory Framework
2.1 FDA vs. HHS Governance & 45 CFR Part 46 2.2 Electronic Records & Signatures (21 CFR Part 11) 2.3 Financial Disclosure Requirements (21 CFR Part 54)
3 Chapter 3: Institutional Review Boards & Informed Consent
3.1 IRB Structure, Roles, and Responsibilities (21 CFR Part 56) 3.2 Informed Consent Core Elements & Process (21 CFR Part 50) 3.3 Informed Consent in Special Circumstances & Exceptions 3.4 Vulnerable Populations & Additional Safeguards (Subparts B, C, D)
4 Chapter 4: Protocol & Essential Documentation
4.1 Protocol Design and Investigator's Brochure (ICH E6 Section 6 & 7) 4.2 Essential Documents Checklist (ICH E6 Section 8) 4.3 Case Report Forms (CRFs) & Source Documentation
5 Chapter 5: Investigational Applications (IND & IDE)
5.1 Investigational New Drug (IND) Applications (21 CFR Part 312) 5.2 Investigational Device Exemptions (IDE) & Device Classification (21 CFR Part 812) 5.3 Expanded Access & Humanitarian Device Exemptions (HDE)
6 Chapter 6: Investigator & Sponsor Responsibilities
6.1 Investigator Responsibilities & Delegation (ICH E6 4.0 / 21 CFR 312.60) 6.2 Sponsor Roles, Responsibilities, and Quality Management (ICH E6 5.0) 6.3 Financial Agreements, Contracts, and Insurance
7 Chapter 7: Study Implementation & Clinical Operations
7.1 Subject Recruitment, Screening, and Enrolling Procedures 7.2 Investigational Product (IP) Receipt, Accountability, and Disposition 7.3 Protocol Compliance, Deviations, and Corrective Action Plans
8 Chapter 8: Safety Definitions & Reporting Workflows
8.1 Adverse Events, Serious Adverse Events, and SUSARs (ICH E2A) 8.2 Safety Reporting Timelines (Investigator-Sponsor-FDA-IRB) 8.3 Device-Related Safety Reporting & Unanticipated Adverse Device Effects (UADEs)
9 Chapter 9: Quality Assurance, Monitoring, and Auditing
9.1 Clinical Site Monitoring (Traditional vs. Risk-Based Monitoring) 9.2 Sponsor Audits vs. Regulatory Inspections 9.3 FDA BIMO Inspections, Form 483, and Warning Letters
10 Chapter 10: Study Closure & Final Disclosures
10.1 Close-Out Visits and Administrative Wrap-Up 10.2 Record Retention Regulations (FDA vs. ICH GCP) 10.3 Final Reporting & Registration (ClinicalTrials.gov / 42 CFR 11)
8.2 Safety Reporting Timelines (Investigator-Sponsor-FDA-IRB)
Key Takeaways Explain This Topic AI
Investigators must report all Serious Adverse Events (SAEs) to the sponsor immediately, defined as within 24 hours of awareness, regardless of causality.
Sponsors must report unexpected fatal or life-threatening suspected adverse reactions (SUSARs) to the FDA within 7 calendar days, followed by a complete report within an additional 8 days.
Other non-fatal or non-life-threatening SUSARs must be reported by the sponsor to the FDA and all participating investigators within 15 calendar days.
Institutional Review Boards (IRBs) must receive prompt reporting of Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs).
When a DSMB is used, its recommendations flow to the sponsor and may drive protocol/ICF changes, enrollment holds, and subsequent IRB/FDA communications—without replacing investigator SAE reporting duties.
Last updated: July 2026
Managing clinical trial safety requires a coordinated network of reporting. When a safety event occurs, specific regulatory timelines govern how information flows from the investigator to the sponsor, and subsequently from the sponsor to regulatory authorities (such as the FDA), other investigators, and Institutional Review Boards (IRBs). Adhering to these timelines is a critical regulatory obligation; failure to report within the mandated timeframes constitutes a serious compliance violation.
The Safety Reporting Chain of Custody
The safety reporting workflow moves through a designated path to ensure proper oversight:
Subject to Investigator: The subject reports an event, or the site staff identifies it through clinical or laboratory assessments.
Investigator to Sponsor: The investigator documents and submits the safety data to the sponsor.
Sponsor to Regulatory Authorities & Investigators: The sponsor evaluates the event's seriousness, causality, and expectedness, and submits expedited reports to the FDA and all participating investigators.
Investigator to IRB: Investigators notify their local IRBs of safety updates and unanticipated problems.
Investigator-to-Sponsor Reporting Timelines
Under FDA regulations (21 CFR 312.64(b)) and ICH GCP E6 (Section 4.11), the investigator must report all serious adverse events (SAEs) to the sponsor immediately , which is operationally defined as within 24 hours of the investigator first becoming aware of the event.
No Causality Filter: The investigator must report the SAE within 24 hours regardless of whether they believe the event is related to the investigational product. The sponsor, not the investigator, is ultimately responsible for making the final determination of expedited reporting to the FDA, though the investigator's assessment is recorded and valued.
Initial Report Content: The initial report must include, at a minimum, the subject's unique identifier, the protocol number, the description of the event, the investigational product exposure details, and the reporter's name. It should not contain direct patient identifiers (such as names or social security numbers) to protect patient privacy.
Follow-Up Reports: The investigator must submit detailed, written follow-up reports as soon as new medical information becomes available (e.g., discharge summaries, laboratory reports, or autopsy findings).
Sponsor-to-FDA Reporting Timelines (21 CFR 312.32)
Sponsors are responsible for evaluating safety information and submitting expedited Investigational New Drug (IND) safety reports to the FDA for events that meet the criteria of a SUSAR. The reporting timelines depend on the severity and outcome of the SUSAR:
7-Day Fatal or Life-Threatening SUSAR Reports
If the SUSAR is fatal or life-threatening , the sponsor must notify the FDA as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information.
Method of Notification: The initial notification can be made by telephone, facsimile, or electronic transmission.
Follow-Up Report: A complete, written report containing all relevant clinical details (often using FDA Form 3500A or a CIOMS I form) must be submitted within an additional 8 calendar days (for a total of 15 calendar days from the initial notification).
15-Day Written IND Safety Reports
For SUSARs that are not fatal or life-threatening (but still serious and unexpected), the sponsor must submit a written IND safety report to the FDA and all participating investigators no later than 15 calendar days after the sponsor determines that the information qualifies for expedited reporting.
Other 15-Day Reporting Triggers: The 15-day timeline also applies to:
Increased Rate of Occurrence: Any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or Investigator's Brochure.
Findings from Other Studies: Findings from animal or in vitro testing (e.g., mutagenicity, teratogenicity, or carcinogenicity) that suggest a significant risk to human subjects.
Reporting Pathway Event Type Timeline Regulatory Basis
Investigator to Sponsor All Serious Adverse Events (SAEs) Immediate / Within 24 hours of awareness 21 CFR 312.64 / ICH E6 4.11
Sponsor to FDA Unexpected Fatal or Life-Threatening SUSARs 7 calendar days (initial); +8 calendar days (complete) 21 CFR 312.32(c)(2)
- Sponsor to FDA Other Serious and Unexpected SUSARs 15 calendar days 21 CFR 312.32(c)(1)
- Sponsor to Investigators Any IND Safety Report (15-day report) 15 calendar days 21 CFR 312.32(c)(1)
- Investigator-to-IRB Reporting Timelines
The Institutional Review Board (IRB) must review safety information that impacts the safety, rights, or welfare of the study subjects. Under 21 CFR 56.108(a)(3) and 45 CFR 46.108(a)(3), institutions must have written procedures to ensure prompt reporting to the IRB of any Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs).
UPIRSO Definition: To qualify as an UPIRSO, an event must meet three criteria:
Unexpected: Not described in the protocol, consent form, or Investigator's Brochure.
Related: There is a reasonable possibility that the incident, experience, or outcome was caused by participation in the research.
Increased Risk of Harm: Suggests that the research places subjects or others at a greater risk of harm than was previously known.
IRB Reporting Timelines: Unlike the rigid FDA timelines, the timeline for reporting to the IRB is defined as "prompt." In practice, local IRBs define "prompt" in their Standard Operating Procedures (SOPs), which commonly specify reporting within 5 to 10 working days for fatal or life-threatening events, and 10 to 15 working days for other unanticipated problems.
Annual Reports (21 CFR 312.33)
Sponsors must submit an IND Annual Report to the FDA within 60 days of the anniversary date that the IND went into effect. Under the international standards, this is often aligned with the Development Safety Update Report (DSUR) (ICH E2F). The annual report must include:
A summary of safety data, including a log of all IND safety reports submitted during the year.
A list of subjects who died during the trial, with a description of the cause of death.
Enrollment updates and status of all ongoing studies under the IND.
Stakeholder Communication and Data Safety Monitoring Boards (DSMBs)
Blueprint Implementation task 2g requires continuous, documented communication among the investigator/site, IRB/IEC, sponsor/CRO, regulatory authorities, and—when constituted—a Data and Safety Monitoring Board (DSMB) / Data Monitoring Committee (DMC).
A DSMB is an independent group of experts that periodically reviews accumulating safety and efficacy data, typically for larger, higher-risk, or blinded trials. Key operational points for CCRP candidates:
The DSMB charter defines meeting cadence, open vs closed sessions, stopping rules, and what the sponsor may see while the trial remains blinded.
DSMB recommendations (continue, modify, pause, or stop) are communicated to the sponsor; the sponsor then determines regulatory/IRB reporting obligations and protocol/ICF changes.
Sites do not usually receive unblinded DSMB datasets; they receive actionable outcomes (for example, a protocol amendment, revised IB safety language, or temporary enrollment hold).
Separately from DSMB review, investigators must still meet routine communication duties: continuing-review packets to the IRB, IND/IDE safety reports and annual reports from the sponsor to FDA and investigators, notification of IRB approval withdrawal, protocol deviations from the investigational plan, and use of investigational product without informed consent when applicable.
Treat the DSMB as an independent safety governance layer—not a substitute for investigator→sponsor SAE reporting or sponsor→FDA IND safety reports.